News End looms for Cassava's simufilam in Alzheimer's disease Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the end
R&D Cassava’s Alzheimer’s drug nears P3 readout, but SEC scandal... Cassava is advancing simufilam through a pivotal phase 3 trial, despite lingering controversy from a SEC investigation.
Spotlight on World Without Disease initiative: 2024 update In a new white paper from the World Without Disease initiative, a 2024 update is provided of the current endeavours and developments that have occurred since inaugural discussions last year
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
